Novo Nordisk's Response to FDA Warning Letter on Ozempic Reporting Issues
Novo Nordisk, the pharmaceutical company responsible for Ozempic, has received a warning letter from the U.S. Food and Drug Administration regarding issues with reporting potential side effects of the diabetes drug. The FDA highlighted three deaths among patients taking semaglutide, the active ingredient in Ozempic and Wegovy, which were not properly reported. One of the deaths was a suicide, and another patient reported suicidal thoughts while on the medication. The FDA emphasized that Novo Nordisk failed to follow protocols for reporting adverse symptoms related to the drug.
During an inspection at Novo Nordisk's U.S. headquarters in Plainsboro, New Jersey, in early 2025, FDA investigators found deficiencies in the company's reporting practices. This inspection was part of the Bioresearch Monitoring Program, which aims to ensure accurate and timely reporting of product safety information to the FDA for monitoring purposes. Novo Nordisk responded to the FDA's warning letter by stating that they have been actively addressing the agency's concerns since the inspection and are committed to complying with post-marketing adverse drug experience regulations.
Novo Nordisk assured the FDA that they take reporting requirements seriously and are working to address the concerns outlined in the warning letter promptly and comprehensively. The company's head of clinical development, medical, and regulatory affairs in the U.S., Anna Windle, expressed confidence in resolving the issues to the FDA's satisfaction. Despite the FDA's recent evaluation finding no link between suicide and GLP-1 drugs like Ozempic and Wegovy, the agency had previously requested the removal of boxed warnings for suicidal behavior or ideation from these medications.
In conclusion, Novo Nordisk is actively addressing the FDA's concerns regarding the reporting of potential side effects of Ozempic and Wegovy. The company is committed to ensuring compliance with post-marketing adverse drug experience regulations and resolving the issues outlined in the warning letter to the FDA's satisfaction.